Optimising the quality of cell-based immunotherapy products is critical to maximising safety and efficacy of novel cancer treatments. Employing the right manufacturing approach is necessary to ensure your product’s long term success.
Join us on 8th February to hear NDAs Dr Paula Salmikangas, Director of Biopharmaceuticals and ATMPs, discuss:
- How the CMC aspects impact safety and efficacy of cell-based cancer immunotherapy products
- The importance of early product characterization
- Cellular markers and correlation with responders
- Critical quality aspects to ensure safety
She will also provide an overview of recent updates in the EU regulatory system for ATMPs.
Dr Salmikangas will be available to answer questions at the end of the session.
